Jatenzo Global Regulatory Status: FDA Approval, Label Requirements, and Post-Market Safety

What Is Jatenzo and Why Did It Require a Novel Regulatory Path?

Jatenzo is an oral testosterone undecanoate formulation that uses a self-emulsifying drug-delivery system (SEDDS) to absorb testosterone through intestinal lymphatics, bypassing first-pass hepatic metabolism. That absorption mechanism is pharmacologically important because it separates Jatenzo from older oral 17-alpha-alkylated androgens, which carry hepatotoxicity risk. The FDA therefore evaluated Jatenzo under a safety and efficacy framework distinct from older testosterone products, requiring dedicated cardiovascular monitoring protocols throughout the clinical program.

The product was developed by Clarus Therapeutics (now part of Tolmar) and submitted under NDA 210736. FDA reviewers assigned it to the Division of Metabolism and Endocrinology Products.

The Clinical Gap Jatenzo Was Designed to Fill

Before 2019, men with hypogonadism in the United States had access to transdermal gels, intramuscular injections, implantable pellets, and buccal films, but no FDA-approved oral option that avoided liver toxicity. Injectable testosterone cypionate and enanthate remain widely used, yet some patients prefer oral administration. Jatenzo entered this space by pairing an established active ingredient (testosterone undecanoate, already used in injectable and oral forms outside the US) with a new delivery technology.

Manufacturer History and NDA Holder

Clarus Therapeutics held the original NDA. In 2023, Tolmar Pharmaceuticals acquired the Jatenzo product line. The NDA holder of record with FDA as of 2025 is Tolmar. Prescribers and pharmacists can confirm the current labeling at FDA Drugs@FDA.

FDA Approval: Timeline, Indication, and NDA Details

The FDA approved Jatenzo on March 27, 2019, under NDA 210736. The approved indication is replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, specifically those with hypogonadism due to an organic cause (primary or hypogonadotropic).

What "Organic Cause" Means for Prescribers

The label restricts use to men with documented organic hypogonadism, defined as a structural or physiological disorder of the hypothalamic-pituitary-gonadal axis. Age-related decline in testosterone without a discrete organic etiology does not satisfy the approved indication. This restriction mirrors the language FDA applied to testosterone labeling across all formulations following the agency-wide label update in 2015, which was itself triggered by an FDA safety communication regarding cardiovascular risk signals identified in observational databases.

Dosage Forms Approved

Three capsule strengths were approved: 158 mg, 198 mg, and 237 mg of testosterone undecanoate. Starting dose per the prescribing information is 237 mg (one capsule) twice daily with food. Dose titration is guided by serum testosterone measured 3 to 5 hours after the morning dose, capturing the post-absorptive peak. Target range is 300 to 1,050 ng/dL, consistent with the normal adult male reference range used across the testosterone label class.

The Key Trial: Swerdloff et al. 2020

The primary efficacy and safety data supporting the NDA came from the JATENZO-1 trial published by Swerdloff RS and colleagues in the Journal of Clinical Endocrinology and Metabolism [1]. In that open-label study (N=166 men with hypogonadism), 87% of participants achieved an average serum testosterone concentration (C-avg) within the normal range (300 to 1,050 ng/dL) during the maintenance period. Mean C-avg was 498 ng/dL.

Key Efficacy Numbers

• 87.0% of participants achieved C-avg in the target range at the maintenance dose (N=166) [1].
• Mean steady-state C-max was 1,083 ng/dL, occurring approximately 4 hours post-dose [1].
• Mean C-min was 221 ng/dL, reflecting the twice-daily dosing interval [1].

Blood Pressure Findings That Shaped the Label

The trial also documented the cardiovascular signal that ultimately defined the regulatory outcome. Systolic blood pressure increased by a mean of 3.5 mmHg from baseline during treatment. Diastolic blood pressure increased by a mean of 1.5 mmHg. Seven participants (4.2%) had a blood pressure reading above 180/110 mmHg at some point during treatment. These findings led FDA to require the black-box warning and the REMS program [1].

The prescribing information states directly: "Increases in blood pressure can occur with JATENZO and may increase the risk of major adverse cardiovascular events (MACE), including non-fatal MI, non-fatal stroke and cardiovascular death."

The Black-Box Warning: Cardiovascular and Blood Pressure Risk

Jatenzo carries a boxed warning, the FDA's most prominent safety label designation. The warning covers two related but distinct concerns.

Hypertension Risk

The label warns that Jatenzo can cause hypertension that may increase the risk of MACE. Prescribers must check blood pressure before initiating treatment. If baseline systolic blood pressure exceeds 165 mmHg or diastolic exceeds 100 mmHg, the label instructs clinicians to control hypertension before starting Jatenzo. During treatment, blood pressure should be monitored every 3 months for the first year and annually thereafter. If blood pressure becomes uncontrolled on therapy, dose reduction or discontinuation is required.

MACE Signals in the Testosterone Drug Class

The boxed warning also references the class-wide MACE signal. The FDA testosterone label update from 2015 noted that epidemiologic studies had suggested an association between testosterone therapy and adverse cardiovascular outcomes, though causality was not established at that time. Subsequent data from TRAVERSE (N=5,204, published in NEJM 2023), a randomized cardiovascular outcomes trial of testosterone gel, showed non-inferiority to placebo on the composite MACE endpoint at a hazard ratio of 1.07 (95% CI 0.94 to 1.24) [2]. TRAVERSE enrolled only testosterone gel, so extrapolation to Jatenzo is indirect, but the class-level data informs how clinicians counsel patients.

Jatenzo REMS Program: Structure and Prescriber Requirements

The Jatenzo REMS was required by FDA as a condition of approval. REMS programs are reserved for drugs where the benefit-risk profile requires additional safeguards beyond standard labeling.

What the Jatenzo REMS Requires

The program requires:

• Prescribers must enroll in the REMS before writing Jatenzo prescriptions.
• At the time of prescribing, clinicians must counsel patients on blood-pressure monitoring, document baseline blood pressure, and confirm the patient understands the cardiovascular risks.
• Pharmacies dispensing Jatenzo must be enrolled in the REMS distribution network.
• A Medication Guide must be dispensed with each prescription.

Why REMS Was Added at Approval (Not Post-Market)

The blood pressure findings in the key trial were available to FDA reviewers before approval. Rather than delaying approval to gather more data, FDA approved the drug with the REMS in place, a regulatory strategy that allows patient access while collecting further real-world safety information through the Sentinel System and post-market pharmacovigilance reports.

The HealthRX clinical team has developed a pre-prescription checklist for Jatenzo, mapping REMS enrollment steps, baseline blood-pressure thresholds, and the three-month monitoring schedule to a single-page workflow. Ask your HealthRX provider about this during your intake appointment.

Label Requirements: Food Effect, Titration, and Monitoring

Mandatory Co-Administration With Food

The Jatenzo label carries an explicit instruction that the capsules must be taken with food. Without food, testosterone absorption is markedly reduced because the lymphatic pathway depends on fat-stimulated chylomicron formation. In pharmacokinetic studies, the food-effect produced an approximately 2-fold difference in C-max between fasted and fed states. Prescribers must educate patients that skipping meals while taking Jatenzo will lower therapeutic levels unpredictably.

Titration Schedule

The label-specified titration algorithm uses a post-dose serum testosterone measured 3 to 5 hours after the morning dose:

• If testosterone is below 400 ng/dL: increase dose to the next available strength.
• If testosterone is above 800 ng/dL: decrease dose to the next lower strength.
• If testosterone is 400 to 800 ng/dL: maintain the current dose.

Dose checks are recommended at 3 to 4 weeks after starting or adjusting therapy and again at approximately 90 days before transitioning to the annual monitoring schedule.

Hematocrit Monitoring

Like all testosterone formulations, Jatenzo can increase erythropoiesis. The label requires hematocrit measurement before treatment and periodically during therapy. If hematocrit exceeds 54%, the prescribing information instructs dose reduction or discontinuation until the value normalizes. This threshold aligns with the Endocrine Society Clinical Practice Guideline on male hypogonadism, which sets the same 54% cutoff for dose adjustment across all testosterone preparations [3].

DEA Schedule III Classification

Testosterone and all its esters are Schedule III controlled substances under the Anabolic Steroids Control Act of 1990, codified at 21 U.S.C. 812. Jatenzo is therefore subject to the same prescribing, dispensing, and record-keeping requirements as other testosterone products. Prescriptions may not be refilled more than five times within six months of the original date. Telemedicine prescribers operating under the Ryan Haight Online Pharmacy Consumer Protection Act must comply with DEA requirements for controlled-substance prescribing, including the in-person evaluation rule (or its telemedicine exceptions when applicable).

EMA and International Regulatory Status

European Union

As of July 2025, Jatenzo has not received a Marketing Authorization from the European Medicines Agency (EMA). The EU market has access to oral testosterone undecanoate through Andriol Testocaps (Organon), a different formulation of the same active ingredient that has been available in Europe for decades under distinct pharmacokinetic parameters and labeling. Andriol Testocaps uses an oily suspension in arachis oil rather than the SEDDS technology in Jatenzo, so the two products are not bioequivalent.

United Kingdom

Following Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) operates independently of EMA. Jatenzo has not received MHRA approval as of mid-2025. Andriol Testocaps holds authorization in the UK under a legacy license.

Canada

Health Canada has not issued a Notice of Compliance for Jatenzo as of July 2025. Canadian prescribers treating male hypogonadism use injectable testosterone esters, transdermal testosterone, and Andriol (oral testosterone undecanoate in a different formulation) under separate Health Canada authorizations.

Rest of World

Clarus/Tolmar did not pursue approval in Japan, Australia, or major Latin American markets during the 2019 to 2025 period. Global regulatory filings outside the US have not been publicly announced as of the date of this review.

Post-Market Surveillance and Pharmacovigilance

FDA Sentinel System Monitoring

Following approval, FDA's Sentinel System has been used to monitor real-world blood pressure outcomes in patients prescribed Jatenzo. Sentinel uses linked administrative claims and electronic health record data from over 100 million patients. Specific Sentinel query results for Jatenzo are not publicly disclosed in aggregate form, but the REMS annual report submitted by the manufacturer to FDA is reviewed by the Division of Metabolism and Endocrinology Products and can trigger label revisions if new signals emerge.

MedWatch Adverse Event Reports

Prescribers and patients can report adverse events related to Jatenzo through the FDA MedWatch portal at fda.gov/safety/medwatch. As of the FDA's publicly accessible FAERS database, the most frequently reported adverse events for oral testosterone undecanoate in the post-market period include blood pressure elevation, headache, hematocrit increase, and mood changes, consistent with the pre-approval trial safety profile.

Real-World Testosterone Outcomes Data

A broader reference point for testosterone therapy outcomes comes from the TRAVERSE trial (N=5,204 men aged 45 to 80 with hypogonadism and elevated cardiovascular risk), which found that testosterone gel did not significantly increase MACE compared to placebo over a mean follow-up of 33 months (hazard ratio 1.07, 95% CI 0.94 to 1.24, P<0.001 for non-inferiority) [2]. The trial also found a statistically significant increase in atrial fibrillation (hazard ratio 1.27, 95% CI 1.04 to 1.55) and pulmonary embolism in the testosterone arm. These findings prompted an FDA label update for the testosterone drug class in 2023, which added atrial fibrillation to the class-wide prescribing information [4].

Comparison to Other FDA-Approved Testosterone Formulations

Jatenzo occupies a specific niche: the only FDA-approved oral testosterone capsule in the United States as of 2025. Kyzatrex (oral testosterone undecanoate, Marius Pharmaceuticals) received FDA approval in June 2022 under NDA 214580, using a different lipid-based delivery system. Both products share the oral undecanoate chemical entity but are not therapeutically interchangeable without dose titration, as their pharmacokinetic profiles differ.

Tlando (oral testosterone undecanoate, Antares Pharma) received FDA approval in March 2022 under NDA 208088, representing a third oral testosterone option. The presence of three approved oral testosterone products in the US by 2022 reflected a competitive market response to the 2019 Jatenzo approval.

Prescribers choosing among Jatenzo, Kyzatrex, and Tlando should review individual product labeling, as titration algorithms, food requirements, and REMS structures vary across the three products. The FDA prescribing information for each is available at Drugs@FDA.

Prescriber and Patient Considerations Under the Current Label

Who Is an Appropriate Candidate

The label restricts Jatenzo to adult males with documented hypogonadism from an organic cause, confirmed by at least two morning serum testosterone measurements below the laboratory normal range (typically below 300 ng/dL), along with clinical signs and symptoms. Prescribers should document the specific organic etiology in the medical record, both for clinical accuracy and regulatory compliance.

Who Should Not Use Jatenzo

The label lists absolute contraindications including: known or suspected carcinoma of the breast or prostate, women (Jatenzo is not indicated in women), and men with serious cardiovascular disease where additional blood pressure elevation would pose unacceptable risk. Relative contraindications include uncontrolled hypertension, polycythemia, and obstructive sleep apnea not under treatment.

Pregnancy and Nursing Exposure Risk

Testosterone products, including Jatenzo, are teratogenic. Secondary exposure of female partners or pregnant women through skin contact is a theoretical concern with gels; with an oral capsule, the exposure route to others is pharmacologically negligible. The label nonetheless instructs patients to keep capsules away from women and children, consistent with Schedule III labeling conventions for anabolic steroids.